doi: 10.3389/fmolb.2023.1170181 Received 20 February 2023 Accepted 28 March 2023 Published 07 April 2023 Volume 10 - 2023 Edited by Catalina Dirney Alba Soto, University of Buenos Aires, Argentina Reviewed by Jacek Mokrosinski, Novo Nordisk Research Center Indianapolis, United States Brian Hudson, University of Glasgow, United Kingdom Updates Copyright 2023 Austin and Tomas
FIGURE 1 GLP-1R is found mainly on the cell membranes of different cell types in the human body
It is commonly prescribed for weight loss in patients who meet certain health criteria
Unlike many weight loss approaches that fight your biology, GLP-1 therapy works with your body's natural systems
Ambery PD, Klammt S, Posch MG et al (2018) MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subjects, randomized, phase 1 study
Published 2021-5-11 Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure
.jpg)
